Literature DB >> 19420170

Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus.

Jana M Swenson1, Karen F Anderson, David R Lonsway, Angela Thompson, Sigrid K McAllister, Brandi M Limbago, Roberta B Carey, Fred C Tenover, Jean B Patel.   

Abstract

We compared the results obtained with six commercial MIC test systems (Etest, MicroScan, Phoenix, Sensititre, Vitek Legacy, and Vitek 2 systems) and three reference methods (agar dilution, disk diffusion, and vancomycin [VA] agar screen [VScr]) with the results obtained by the Clinical and Laboratory Standards Institute broth microdilution (BMD) reference method for the detection of VA-intermediate Staphylococcus aureus (VISA). A total of 129 S. aureus isolates (VA MICs by previous BMD tests, <or=1 microg/ml [n = 60 strains], 2 microg/ml [n = 24], 4 microg/ml [n = 36], or 8 microg/ml [n = 9]) were selected from the Centers for Disease Control and Prevention strain collection. The results of BMD with Difco Mueller-Hinton broth were used as the standard for data analysis. Essential agreement (percent +/-1 dilution) ranged from 98 to 100% for all methods except the method with the Vitek Legacy system, for which it was 90.6%. Of the six commercial MIC systems tested, the Sensititre, Vitek Legacy, and Vitek 2 systems tended to categorize VISA strains as susceptible (i.e., they undercalled resistance); the MicroScan and Phoenix systems and Etest tended to categorize susceptible strains as VISA; and the Vitek Legacy system tended to categorize VISA strains as resistant (i.e., it overcalled resistance). Disk diffusion categorized all VISA strains as susceptible. No susceptible strains (MICs <or= 2 microg/ml) grew on the VScr, but all strains for which the VA MICs were 8 microg/ml grew on the VScr. Only 12 (33.3%) strains for which the VA MICs were 4 microg/ml grew on VScr. The differentiation of isolates for which the VA MICs were 2 or 4 microg/ml was difficult for most systems and methods, including the reference methods.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19420170      PMCID: PMC2708520          DOI: 10.1128/JCM.00221-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

Review 1.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

Authors:  Fred C Tenover; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2007-03-28       Impact factor: 9.079

2.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.

Authors:  F C Tenover; M V Lancaster; B C Hill; C D Steward; S A Stocker; G A Hancock; C M O'Hara; S K McAllister; N C Clark; K Hiramatsu
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

3.  Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

Authors:  Ronald N Jones; Matthew G Stilwell; Helio S Sader; Thomas R Fritsche; Beth P Goldstein
Journal:  Diagn Microbiol Infect Dis       Date:  2006-01-19       Impact factor: 2.803

4.  In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.

Authors:  M J Rybak; E Hershberger; T Moldovan; R G Grucz
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

5.  A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.

Authors:  Mandy Wootton; Alasdair P MacGowan; Timothy R Walsh; Robin A Howe
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

Review 6.  Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Peter C Appelbaum
Journal:  Int J Antimicrob Agents       Date:  2007-09-20       Impact factor: 5.283

7.  Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.

Authors:  Jennifer M Streit; Ronald N Jones; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2004-02-25       Impact factor: 5.790

  7 in total
  37 in total

1.  A report on the first case of vancomycin-intermediate Staphylococcus aureus (VISA) in Hawai'i.

Authors:  Suttirak Chaiwongkarjohn; Pornpoj Pramyothin; Nuntra Suwantarat; Matthew J Bankowski; Terrie Koyamatsu; Steven E Seifried; Erlaine F Bello
Journal:  Hawaii Med J       Date:  2011-11

2.  Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods.

Authors:  Rodrigo M Paiva; Alice B Mombach Pinheiro Machado; Alexandre P Zavascki; Afonso L Barth
Journal:  J Clin Microbiol       Date:  2010-09-22       Impact factor: 5.948

3.  Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.

Authors:  Riad Khatib; Kathleen Riederer; Mamta Sharma; Stephen Shemes; Sugantha P Iyer; Susan Szpunar
Journal:  J Clin Microbiol       Date:  2015-08-26       Impact factor: 5.948

4.  Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.

Authors:  K Riederer; S Shemes; P Chase; A Musta; A Mar; R Khatib
Journal:  J Clin Microbiol       Date:  2011-04-13       Impact factor: 5.948

Review 5.  Expert systems in clinical microbiology.

Authors:  Trevor Winstanley; Patrice Courvalin
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

6.  Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus.

Authors:  Mark C Kruzel; Cole T Lewis; Kerry J Welsh; Evan M Lewis; Nicola E Dundas; John F Mohr; Lisa Y Armitige; Audrey Wanger
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

7.  Clonal spreading of methicillin-resistant SCCmec Staphylococcus aureus with specific spa and dru types in central Taiwan.

Authors:  C-M Ho; M-W Ho; C-Y Lee; N Tien; J-J Lu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-26       Impact factor: 3.267

8.  Reduced Vancomycin Susceptibility of Methicillin-Susceptible Staphylococcus aureus Has No Significant Impact on Mortality but Results in an Increase in Complicated Infection.

Authors:  Sean B Sullivan; Eloise D Austin; Stephania Stump; Barun Mathema; Susan Whittier; Franklin D Lowy; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

9.  Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods.

Authors:  Michael J Rybak; Celine Vidaillac; Helio S Sader; Paul R Rhomberg; Hossein Salimnia; Lawrence E Briski; Audrey Wanger; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2013-04-17       Impact factor: 5.948

10.  Novel screening agar for detection of vancomycin-nonsusceptible Staphylococcus aureus.

Authors:  Carey-Ann D Burnham; Carol J Weber; W Michael Dunne
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.